Skip to content

Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.

Performance Assessment of High Throughput Sequencing for the Detection of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02007642
Acronym
PATHOQUEST1
Enrollment
250
Registered
2013-12-11
Start date
2013-10-31
Completion date
2014-10-31
Last updated
2015-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunodeficiency and Suspected Infection

Brief summary

The study patients are patients suffering from primary or secondary immunodeficiencies investigated in the Hospital Necker for a suspected infectious disease. The study purpose is to assess the performance of a High Throughput Sequencing method, the PATHOQUEST method (from sample preparation to bio informatic analysis), versus the classic diagnostic approach. The study will evaluate the capacity of the PATHOQUEST method to detect pathogens responsible for an infectious disease episode and will also evaluate the delay of obtention of results compared to the classic diagnostic approach.

Interventions

PROCEDUREBlood sampling / Body fluid sampling

During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method. Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite...

Sponsors

Imagine Institute
CollaboratorOTHER
Pathoquest
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Summary of inclusion criteria: 1. Primary or secondary immunodeficiencies defined by * Solid organ transplantation and immunosuppressive drug * Recent chemotherapy * Hematopoïetic Stem Cells transplantation * Primary immune deficiency * Auto-immune disease * HIV infection 2. Infection suspicion 3. Microbiological investigation 4. Adult or child above 1 year 5. Hospitalization at Necker-Enfants malades hospital 6. Registration to Healthcare organism 7. ICF signature Summary of

Exclusion criteria

1. Obvious diagnosis following clinical examination 2. Participation in a clinical trial for a new drug 3. People under legal guardianship 4. People unable to fulfil the required medical follow-up

Design outcomes

Primary

MeasureTime frameDescription
Identification of pathogens responsible for the infection1 yearThe primary outcome will assess the number of diagnostics obtained by the PATHOQUEST method and classic diagnostic approach.

Secondary

MeasureTime frameDescription
Delay of obtention of diagnostic1 yearThe delay of obtention of results will be compared to determine which approach allows an earlier diagnosis.
Economic impact of the PATHOQUEST method1 yearComparison of the cost of the classic diagnostic approach and PATHOQUEST method, including cost of the hospital stay, microbiological tests performed, empirical anti-infectious drugs prescribed.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026